Calponin 1 Antibody (0.N.39): sc-70487

Calponin 1 Antibody (0.N.39) is a mouse monoclonal IgG1 antibody that detects Calponin 1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Calponin 1 is a crucial actin- and tropomyosin-binding protein that plays a significant role in regulating smooth muscle contraction and serves as a marker for smooth muscle cell differentiation. Anti-Calponin 1 antibody (0.N.39) targets proteins primarily located in smooth muscle tissues, where Calponin 1 interacts with F-Actin to inhibit actomyosin activity, thereby modulating muscle contraction. Calponin 1′s function lies in maintaining the contractile state of smooth muscle, which is essential for various physiological processes, including blood vessel regulation and gastrointestinal motility. Calponin 1 activity can be altered through post-translational modifications, particularly phosphorylation at Serine 175 by protein kinase C or calmodulin-dependent protein kinase II, which leads to a loss of inhibitory properties. The presence of three distinct forms—Calponin 1, Calponin 2, and Calponin 3—highlights functional diversity across different tissues, with Calponin 2 also found in heart muscle and Calponin 3 in the brain, further emphasizing Calponin 1′s critical role in muscle physiology and cellular signaling.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Calponin 1 Antibody (0.N.39) References:

1. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats.  |  Castro, MM., et al. 2012. Arterioscler Thromb Vasc Biol. 32: 662-8. PMID: 22199370
2. Anti-calponin 1 antibodies highlight intracytoplasmic inclusions of infantile digital fibromatosis.  |  Henderson, H., et al. 2014. Histopathology. 64: 752-5. PMID: 24117680
3. Calponin1 inhibits dilated cardiomyopathy development in mice through the εPKC pathway.  |  Lu, D., et al. 2014. Int J Cardiol. 173: 146-53. PMID: 24631115
4. Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties.  |  Yamane, T., et al. 2015. Anticancer Res. 35: 5993-9. PMID: 26504022
5. Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension.  |  Belo, VA., et al. 2016. Biochem Pharmacol. 118: 50-58. PMID: 27531060
6. Maternal serum calponin 1 level as a biomarker for the short-term prediction of preterm birth in women with threatened preterm labor.  |  Cetin, O., et al. 2018. J Matern Fetal Neonatal Med. 31: 216-222. PMID: 28068849
7. Matrix Metalloproteinase-2 Activity is Associated with Divergent Regulation of Calponin-1 in Conductance and Resistance Arteries in Hypertension-induced Early Vascular Dysfunction and Remodelling.  |  Parente, JM., et al. 2017. Basic Clin Pharmacol Toxicol. 121: 246-256. PMID: 28374979
8. Actin cytoskeleton mediates BMP2-Smad signaling via calponin 1 in preosteoblast under simulated microgravity.  |  Xu, H., et al. 2017. Biochimie. 138: 184-193. PMID: 28457943
9. Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension.  |  Blascke de Mello, MM., et al. 2019. Vascul Pharmacol. 116: 36-44. PMID: 30339939
10. Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition.  |  Mitchell, E., et al. 2020. Mol Carcinog. 59: 701-712. PMID: 32134153

The preferred Calponin 1 antibody is Calponin 1 Antibody (CALP): sc-58707.